CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study
Journal of Cystic Fibrosis · 2025
DOI: 10.1016/j.jcf.2025.03.002 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Cystic Fibrosis, 2025. Verfasst von Laurent Chouchana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regional Center of Pharmacovigilance, Department of perinatal, pediatric and adult pharmacology, Hopital Cochin, Hopital Necker, AP-HP. Paris, France…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pregnancy Outcome, Cystic Fibrosis Transmembrane Conductance Regulator, Chloride Channel Agonists. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVES: Recent therapeutic advances, mainly with the advent of CFTR modulators, have been associated with an increasing number of pregnancies in females with cystic fibrosis (fwCF). This study aimed to evaluate the safety of the use of CFTR modulators, specifically elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) during pregnancy. METHODS: A nationwide cohort study was conducted using the French health insurance data warehouse (SNDS), covering nearly all singleton pregnancies ending between January 2018 and December 2023. Exposure to CFTR modulators was defined as using prescriptions through pregnancy, including one month in the preconception period. The study compared pregnancy outcomes amongst fwCF between pregnancies exposed and unexposed to CFTR modulators. RESULTS: Among 590 pregnancies in fwCF, 148 (24.7 %) were exposed to CFTR modulators, including 136 during first trimester. Of these, 147 (99.3 %) resulted in livebirths. The most common CFTR modulator used was ELX/TEZ/IVA, in 121 (81.8 %) pregnancies. The prevalence of major birth defects was similar between exposed and unexposed fwCF (3.38 % vs. 4.66 %; p = 0.72). The rate of small for gestational age (SGA,
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regional Center of Pharmacovigilance, Department of perinatal, pediatric and adult pharmacology, Hopital Cochin, Hopital Necker, AP-HP. Paris, France; Université Paris Cité, INSERM UMR 1343 « Pharmacologie et évaluation…
- Université Paris Cité, INSERM UMR 1343 « Pharmacologie et évaluation des thérapeutiques chez l'enfant et la femme enceinte ». Paris, France; Clinical Research Unit Cochin Necker, AP-HP. Paris, France.
- Université Paris Cité, INSERM U1016, Institut Cochin, Paris, France; Cystic Fibrosis National Reference Center and Respiratory Medicine, Hopital Cochin, AP-HP. Paris, France.
Zitieren
APA
Chouchana, L., Collier, M., Martin, C., Burgel, P. R., & Treluyer, J. M. (2025). CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2025.03.002
Vancouver
Chouchana L, Collier M, Martin C, Burgel PR, Treluyer JM. CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study. Journal of Cystic Fibrosis. 2025. doi:10.1016/j.jcf.2025.03.002
BibTeX
@article{Chouchana2025,
author = {Chouchana, Laurent and Collier, Mathis and Martin, Clémence and Burgel, Pierre-Régis and Treluyer, Jean-Marc},
title = {CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study},
journal = {Journal of Cystic Fibrosis},
year = {2025},
doi = {10.1016/j.jcf.2025.03.002}
}
EUVIMED